Table 2.

Characteristics of the Independent Data Sets Used for Validation of the GRS

GEO Accession	GSE1898-GSE4024	GSE14520
Abbreviation used	LEC (Laboratory of Experimental Carcinogenesis)	NCI (National Cancer Institute)
Related publication	[11]	[12]
Microarray platform	NCI/ATC Hs-OperonV2	Affymetrix Human Genome U133A 2.0 Array
Number of GRS genes available	6/7	6/7
Number of patients	67	231
Gender (male/female/NA)	46/21/0	201/27/3
Age in years [median (min-max)]	59 (26-85)	50 (21-77)
Cirrhosis (yes/no/NA)	41/26/0	211/17/3
Tumor size (< 5 cm/> 5cm/NA)	28/21/7	145/82/4
TNM stage (I/II/III/NA)	3/9/27/28	93/75/38/25
BCLC stage (0/A/B/C/NA)	NA	20/144/22/26/19
aFP levels (< 300 ng/ml/> 300 ng/ml/NA)	36/25/6	120/104/7
Median follow-up in months (min-max)	65 (0.1-169)	51.9 (1.8-67.4)

NA, not available; aFP, alpha-fetoprotein.

More detailed information can be found at http://www.ncbi.nlm.nih.gov/geo/.